Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

The resilience of an aging world
With global populations over 65 expected to double by 2050, aging is often seen as a risk multiplier. Yet it can also be a source of resilience. Dur
How to unlock true value from workplace pensions
Workplace pensions are one of employers’ most powerful tools to support their people’s financial wellbeing, engagement and long-term retention. But d
Engagement - the underused risk management tool
Defined contribution pension schemes are seen as low risk for employers, but if staff don’t understand and appreciate them, the risks can add up. With

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.